Trial Profile
The effects of IFN-free 2D regimen (ombitasvir/paritaprevir/ritonavir) on host immune responses against hepatitis C virus
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 May 2016
Price :
$35
*
At a glance
- Drugs Ombitasvir/paritaprevir/ritonavir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 26 May 2016 New trial record